Given the link between obesity, insulin resistance (metabolic syndrome, type 2 diabetes mellitus), and a spectrum of cardiovascular diseases, including PAD, the impact of ghrelin on vascular dysfunction in patients with these comorbidities warrants investigation [38]. Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.